课题基金 / 基金详情

GABAB receptors in the hippocampus: allosteric modulation and receptor isoforms.

GABAB receptors in the hippocampus: allosteric modulation and receptor isoforms.
海马中的 GABAB 受体:变构调节和受体亚型。
批准号:
BB/E010296/1
负责人:
Ying Chen
金额:
$48.36万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2007
资助国家:
英国
项目状态:
已结题
起止时间:
2007 至 --

项目摘要

项目成果

Ying Chen的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The GABAB receptors belong to a family of specialised brain signalling molecules sensing the inhibitory neurotransmitter GABA. The GABAB receptors have been shown to participate in essential functions of the nervous system, like pain sensation, reward and learning and memory, and are hence important therapeutic targets for various diseases, including spasticity, epilepsy, pain and addiction. Baclofen (Lioresal), a molecule that can activate the GABAB receptors, is a muscle relaxant and currently used clinically to treat spasticity. Recently, molecules were also identified to enhance the function of the GABAB receptors by an alternative way of allosteric modulation, and these molecules were found effective in treating addiction and anxiety in animal models. These GABAB receptor potentiators may, thus, become a new class of therapeutics for psychiatric and neurological disorders. However, the detailed mechanisms underlying the actions of these new GABAB potentiators are still poorly understood. In this basic scientific project, we designed a series of experiments aiming to elucidate the mechanisms of the GABAB potentiators in neuronal signalling. Detailed electrophysiological and pharmacological characterization combined with genetic manipulations on GABAB receptor expression will be carried out in the context of neuronal signalling in brain tissues. The further understanding of the GABAB receptor functional modulations will aid the development of newer and more effective drugs for psychiatric and neurological disorders with reduced side effects. Major pharmaceutical companies have shown keen interests in this new drug target.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1096/fj.13-243295
发表时间: 2014-11
期刊: FASEB journal : official publication of the Federation of American Societies for Experimental Biology
影响因子: --
作者: [Wu C, Sui G, Archer SN, Sassone-Corsi P, Aitken K, Bagli D, Chen Y]
通讯作者: Chen Y
XIII Mediterranean Conference on Medical and Biological Engineering and Computing 2013
2013 年第十三届地中海医学和生物工程与计算会议
DOI: 10.1007/978-3-319-00846-2_142
发表时间: 2014
期刊:
影响因子: --
作者: [Abásolo D]
通讯作者: Abásolo D
Open Access Block Award 2024 - SOAS University of London
Open Access Block Award 2023 - SOAS University of London
Open Access Block Award 2022 - SOAS University of London
Dynamic protein-based biomaterial designs for bionic coatings
  • 批准号:
    2104294
  • 项目类别:
    Continuing Grant
  • 资助金额:
    $52.5万
  • 财政年份:
    2021
  • 负责人:
    Ying Chen
  • 依托单位:
国内基金
海外基金
生物钟核受体Rev-erbα在缺血性卒中神经元能量代谢中的改善作用及机制研究
  • 批准号:
    82371332
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    胡琴
  • 依托单位:
BMP9/BMP type I receptors 通过激活 PPARα保护心肌梗死的机制研究
  • 批准号:
    LQ22H020003
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    陈灵丽
  • 依托单位:
C型凝集素样受体识别在原发性皮肤毛霉病中的作用
  • 批准号:
    81171510
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2011
  • 负责人:
    李若瑜
  • 依托单位:
Toll样受体在糖尿病视网膜病变中作用及其可能信号传导机制
  • 批准号:
    81141008
  • 项目类别:
    专项基金项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2011
  • 负责人:
    王康
  • 依托单位: